Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Valeant Pharmaceuticals International Inc (NYSE:VRX)

16.18
Delayed Data
As of Feb 24
 -0.40 / -2.41%
Today’s Change
13.00
Today|||52-Week Range
86.50
+11.43%
Year-to-Date
Berkshire Letter Highlights: Buffett Hates Hedge Funds, Likes Immigrants And The US O...
10:41am / Investing Channel - Paid Partner Content
Silver Point Capital L.P. Buys Basic Energy Services, Key Energy Services, Penn Virgi...
Feb 22 / GuruFocus News - Paid Partner Content
Saba Capital Management, L.P. Buys Allergan PLC, Alpine Total Dynamic Dividend Fund, ...
Feb 23 / GuruFocus News - Paid Partner Content
Valeant Acquires Eyegate Licensing Rights
Feb 21 / TheStreet.com - Paid Partner Content
Allergan Lacks Interest in Valeant
Feb 23 / TheStreet.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Alle...
Feb 21 / Zacks.com - Paid Partner Content
Frontrunning: February 23
Feb 23 / Investing Channel - Paid Partner Content
This Guru Loves Valeant; Should You?
Feb 20 / GuruFocus News - Paid Partner Content
Futures Flat, Global Stocks Near Record High After Minutes Fail To Spark Dollar Rally
Feb 23 / Investing Channel - Paid Partner Content
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
Feb 17 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close16.58
Today’s open16.42
Day’s range16.10 - 16.53
Volume10,635,267
Average volume (3 months)17,384,282
Market cap$5.5B
Dividend yield--
Data as of 4:01pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-131.25%
Earnings growth (this year)-46.60%
Earnings growth (next 5 years)+9.40%
Revenue growth (last year)+26.42%
P/E ratioNM
Price/Sales3.32
Price/Book0.94

Competitors

 Today’s
change
Today’s
% change
MNKMallinckrodt Plc-1.09-2.00%
IONSIonis Pharmaceutical...+0.24+0.54%
TAROTaro Pharmaceutical ...-2.36-1.98%
ACADACADIA Pharmaceutica...-0.68-1.72%
Data as of 4:02pm ET, 02/24/2017

Financials

Next reporting dateFebruary 28, 2017
EPS forecast (this quarter)$1.21
Annual revenue (last year)$10.4B
Annual profit (last year)-$291.7M
Net profit margin-2.79%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chairman &
Chief Executive Officer
Joseph C. Papa
Chief Financial Officer &
Executive VP-Finance
Paul S. Herendeen
Corporate headquarters
Laval, Quă©bec

Forecasts


Search for Jobs